

International Office Rue de Lausanne 78 CP 116 1211 Geneva 21 Switzerland

Phone: +41 (0)22 8498400 Fax: +41 (0) 22 849 84 04

www.msf.org

## F.3 - Proposal for the addition of new antibiotic formulations to the WHO Model List of Essential Medicines

MSF supports the addition of all the new antibiotics formulations proposed in the application, for all the indications proposed for each new formulation, in the section 6.2. Antibacterials, in the WHO Model List of Essential Medicines (EML).

The new strength formulations are higher than the formulations already listed in the EML and are aligned with the dosing needs of adult patients. The addition of this new dosages forms will allow a reduced daily pill burden for adult patients, therefore, a better adherence to treatment. For injectable, it will also ease the supply and stock management.

The application concerns the addition, in section 6.2.1 Access group antibiotics, of the following formulations:

- Amoxicillin 1g solid oral dosage form, to already listed 250 mg, 500 mg solid oral dosage forms and 125mg/5 ml, 250mg/5ml powder for oral liquid.
- Cefalexin 500 mg solid oral dosage form, to already listed 250 mg solid oral dosage forms and 125 mg/5 ml, 250 mg/5ml powder for oral liquid.
- Clindamycin 600 mg and 900 mg injection, to already listed 150 mg/ml injection.
- Phenoxymethylpenicillin 500 mg tablet to already listed 250 mg tablet and 250 mg/5 ml powder for oral liquid.

The application concerns the addition, in the core list of section 6.2.2 Watch group antibiotics, of the following formulations:

- Ceftriaxone 2 g powder for injection to already listed 250 mg and 1 g powder for injection.
- Ciprofloxacin 500 mg tablet to already listed 250 mg tablet and 250 mg/5 ml oral liquid.

The application concerns the addition, in the complementary list of section 6.2.2 Watch group antibiotics:

• Vancomycin 500 mg and 1 g powder for injection to the already listed 250 mg powder for injection.

MSF is using amoxicillin, cefalexin, ceftriaxone, ciprofloxacin, clindamycin, phenoxymethylpenicillin and vancomycin in its programs.

MSF urges the 23<sup>rd</sup> Expert Committee on the Selection and Use of Essential Medicines to add all the formulations listed in the application, for all the indications listed for each new formulation, in the section 6.2. Antibacterials in the WHO Model List of Essential Medicines.

For Médecins Sans Frontières

Myriam Henkens, MD, MPH International Medical

Coordinator